neuroleptic malignant syndrome
Summary: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
Publications208 found, 100 shown here
- Lethal catatoniaVladan Ljubisavljevic
Aust N Z J Psychiatry 36:563-4. 2002
- Neuroleptic malignant syndrome and atypical antipsychotic drugsJambur Ananth
University of California, Los Angeles, CA, USA
J Clin Psychiatry 65:464-70. 2004OBJECTIVE: The incidence of neuroleptic malignant syndrome (NMS) is not known, but the frequency of its occurrence with conventional antipsychotic agents has been reported to vary from 0.02% to 2.44%...
- Comments on the report of neuroleptic malignant syndrome induced by ziprasidoneBranimir Margetic
World J Biol Psychiatry 8:131-2; author reply 133-4. 2007
- Neuroleptic malignant syndromeJeffrey R Strawn
University of Cincinnati, Department of Psychiatry, College of Medicine, Box 670559, Cincinnati, OH 45267-0559, USA
Am J Psychiatry 164:870-6. 2007
- Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndromeFeriha Ozer
Department of Neurology, Bakirkoy Neurology Center, Istanbul, Turkey
J ECT 21:125-7. 2005..A patient with Parkinson disease, major depression, and paranoid psychosis who developed neuroleptic malignant syndrome (NMS) as the result of the sudden termination of high-dose (1200 mg/d) levodopa treatment is presented ..
- Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidolCassandra J Bellamy
Department of Pharmacy, Medical Intensive Care Unit, Hospital of University of Pennsylvania, USA
J Trauma 66:954-8. 2009..used to treat agitation in critically ill patients, has been associated with the development of neuroleptic malignant syndrome (NMS)...
- The evaluation and management of patients with neuroleptic malignant syndromeMinal J Bhanushali
Department of Neurology, University of Minnesota, Minneapolis, Minnesota 55455, USA
Neurol Clin 22:389-411. 2004..Definitive treatment guidelines remain an important issue to be addressed. Efforts have been initiated in that direction and all cases can be reported on a toll-free hotline ( 1-888-667-8367) or online (www.nmsis.org)...
- Successful treatment of a complicated case of neuroleptic malignant syndromeA Lappa
Intensive Care Unit, M G Vannini Hospital, Via A Bullicante no 4, 00177 Rome, Italy
Intensive Care Med 28:976-7. 2002b>Neuroleptic malignant syndrome (NMS) is a life-threatening reaction often related to neuroleptic drugs, characterized by rigidity, hyperthermia, altered consciousness, and fluctuating blood pressure...
- The WHO analgesic ladder and neuroleptic malignant syndromeY Asakura
Acta Anaesthesiol Scand 50:1311-2. 2006
- An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi methodRonald J Gurrera
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
J Clin Psychiatry 72:1222-8. 2011The lack of generally accepted diagnostic criteria for neuroleptic malignant syndrome (NMS) impedes research and clinical management of patients receiving antipsychotic medications...
- Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitationVivek Kadyan
Department of Physical Medicine and Rehabilitation, The Ohio State University Medical Center, Columbus, OH, USA
Brain Inj 17:631-7. 2003b>Neuroleptic malignant syndrome is a rare disorder that manifests with hyperthermia, muscle rigidity and autonomic instability...
- Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case reportRhonda Malyuk
Department of Pharmacy, Riverview Hospital, Port Coquitlam, BC, Canada
Int J Geriatr Psychiatry 17:326-8. 2002We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history...
- Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndromeJui Hsiu Tsai
Department of Psychiatry, Kaohsiung Medical University Hsiaokang Hospital, Kaohsiung, Taiwan
Pharmacotherapy 25:1156-9. 2005..b>Neuroleptic malignant syndrome (NMS) was diagnosed...
- Olanzapine-associated neuroleptic malignant syndromeNick B Norgard
Department of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 73117 5040, USA
Pharmacotherapy 26:1180-2. 2006b>Neuroleptic malignant syndrome (NMS) is a rare but potentially serious complication of neuroleptic drugs. It may vary in both presenting characteristics and severity...
- Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndromeRachel E Dew
Department of Psychiatry, Wake Forest University Baptist Medical Center, Winston Salem, NC 27157, USA
Int J Adolesc Med Health 17:187-8. 2005b>Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic.
- Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescentsGil Zalsman
Adolescence Inpatient Unit, Geha Psychiatric Hospital, Petach Tiqva, Israel
Int J Adolesc Med Health 16:179-82. 2004b>Neuroleptic Malignant Syndrome (NMS) is a known, life threatening, side effect of classical antipsychotic drugs...
- Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndromeSebahattin Vurucu
Department of Pediatrics, Gulhane Military Medical Academy, Ankara, Turkey
J Natl Med Assoc 101:273-5. 2009..b>Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the ..
- Neuroleptic malignant syndrome associated with atypical antipsychotic drugsJulian N Trollor
School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia
CNS Drugs 23:477-92. 2009b>Neuroleptic malignant syndrome (NMS) is a rare but potentially severe idiosyncratic adverse reaction usually seen in the context of treatment with antipsychotic drugs...
- Neuroleptic malignant syndrome without neurolepticsK C Ong
Department of Respiratory and Critical Care Medicine, Singapore General Hospital
Singapore Med J 42:85-8. 2001b>Neuroleptic malignant syndrome is an uncommon condition characterised by hyperthermia, rigidity, altered mentation and autonomic instability...
- Catatonia is a risk factor for neuroleptic malignant syndromeBrendan T Carroll
J Clin Psychiatry 65:1722-3. 2004
- Neuroleptic malignant syndrome and catatonia. A report of three casesM Raja
Ospedale Santo Spirito, Dipartimento di salute mentale USL RM11, Rome, Italy
Eur Arch Psychiatry Clin Neurosci 243:299-303. 1994In a series of 1007 consecutively admitted patients, 3 cases of neuroleptic malignant syndrome (NMS) were identified (0.3%)...
- Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapineThomas Paparrigopoulos
Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece
World J Biol Psychiatry 10:70-3. 2009..abnormalities and shares many clinical, biological and treatment response features with the neuroleptic malignant syndrome (NMS), a rare adverse reaction to psychoactive medications...
- Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophreniaAshish Srivastava
Institute of Psychiatry and Human Behaviour, Bambolim, Goa, India
Psychiatry Clin Neurosci 63:119-21. 2009A case of a male patient with schizophrenic illness who developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine is reported...
- Neuroleptic malignant syndrome: case report and discussionGeethan J Chandran
Department of General Surgery, University of Saskatchewan, Saskatoon, SK
CMAJ 169:439-42. 2003We report a case involving an 81-tear-old man with schizoaffective disorder who presented with neuroleptic malignant syndrome (NMS) after an increase in his neuroleptic dose...
- Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medicationM Stotz
Department of Anaesthesia, University of Basel Kantonsspital, CH 4031 Basel, Switzerland
Br J Anaesth 93:868-71. 2004b>Neuroleptic malignant syndrome is a rare complication when using neuroleptic drugs...
- Possible neuroleptic malignant syndrome associated with paliperidoneHarpreet S Duggal
J Neuropsychiatry Clin Neurosci 19:477-8. 2007
- Neuroleptic malignant syndrome due to three atypical antipsychotics in a childDong-Seon Chungh
Division of Child and Adolescent Psychiatry, Department of Psychiatry, Seoul National University Bundang Hospital, Seoul, Korea
J Psychopharmacol 19:422-5. 2005b>Neuroleptic Malignant Syndrome (NMS) is a rare, potentially fatal and idiosyncratic drug reaction...
- Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndromeJoseph W Y Lee
Graylands Hospital and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia
Ann Clin Psychiatry 19:9-16. 2007This case series study examines the hypothesis that neuroleptic malignant syndrome (NMS) is a heterogeneous condition including catatonic variants and non-catatonic pathological reactions to antipsychotics.
- Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a reviewRachel Neuhut
Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
J Child Adolesc Psychopharmacol 19:415-22. 2009b>Neuroleptic malignant syndrome (NMS) is a severe iatrogenic complication of treatment with antipsychotic medication...
- Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literatureDallas P Seitz
Department of Psychiatry, Queen s University, Kingston, Ontario, Canada
Psychosomatics 50:8-15. 2009b>Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics.
- Neuroleptic malignant syndrome induced by atypical antipsychoticsDebra K Farver
South Dakota State University, South Dakota Human Services Center, PO Box 76, Yankton, SD 57078, USA
Expert Opin Drug Saf 2:21-35. 2003A review of the English literature confirms that neuroleptic malignant syndrome (NMS) occurs with both traditional and atypical antipsychotic medications...
- Neuroleptic malignant syndrome with aripiprazole and lithium: a case reportSyed Ali
J Clin Psychopharmacol 26:434-6. 2006
- Clinical risk factors for neuroleptic malignant syndromeDomenico Berardi
Institute of Psychiatry, Bologna University
Hum Psychopharmacol 17:99-102. 2002Pharmacological risk factors for neuroleptic malignant syndrome (NMS) are better defined than clinical risk factors. We examined the psychopathological status preceding the onset of NMS in 20 patients...
- Neuroleptic malignant syndrome associated with ziprasidone in an adolescentJoseph Leibold
Department of Emergency Medicine, Wright State University, Ohio, USA
Clin Ther 26:1105-8. 2004BACKGROUND: Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal disorder characterized by fever, muscular rigidity, delirium, and autonomic instability...
- Atypical neuroleptic malignant syndrome: diagnostic controversies and considerationsLara S Picard
Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
Pharmacotherapy 28:530-5. 2008b>Neuroleptic malignant syndrome (NMS) is a serious and potentially fatal adverse effect of antipsychotic drugs. The diagnosis of NMS commonly requires core symptoms of hyperthermia and muscle rigidity...
- Neuroleptic Malignant Syndrome with ziprasidoneRadhika G Murty
J Clin Psychopharmacol 22:624-6. 2002
- Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuationD N Mendhekar
Aust N Z J Psychiatry 39:947-8. 2005
- Genotype A1/A2 associated with neuroleptic malignant syndromeM Del Tacca
Bipolar Disord 7:390-1. 2005
- Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agentsB Spivak
Research Unit, Ness Ziona Government Psychiatric Hospital, Israel
Int Clin Psychopharmacol 11:207-9. 1996b>Neuroleptic malignant syndrome (NMS) is a severe side-effect of neuroleptic treatment. It is usually related to hypodopaminergic activity...
- Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndromeR J Gurrera
Department of Psychiatry, Harvard Medical School, Brockton West Roxbury DVA Medical Center, Brockton, MA 02301, USA
Am J Psychiatry 156:169-80. 1999The author's goal was to develop a pathophysiological model for neuroleptic malignant syndrome with greater explanatory power than the alternative hypotheses of hypothalamic dopamine antagonism (elevated set point) and direct myotoxicity (..
- Recognizing neuroleptic malignant syndromePatricia I Rosebush
CMAJ 170:1645. 2004
- Olanzapine-associated neuroleptic malignant syndromeVassilis P Kontaxakis
Department of Psychiatry, Eginition Hospital, University of Athens, 74, Vas Sophias Avenue, 11528 Athens, Greece
Prog Neuropsychopharmacol Biol Psychiatry 26:897-902. 2002b>Neuroleptic malignant syndrome (NMS) is an uncommon but serious idiosyncratic reaction associated with antipsychotic medication...
- Intrathecal baclofen withdrawal simulating neuroleptic malignant syndrome in a child with cerebral palsyL Samson-Fang
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City 84132, USA
Dev Med Child Neurol 42:561-5. 2000..His clinical course is compared to that of adults experiencing withdrawal from IBI and to neuroleptic malignant syndrome. If unrecognized, this disorder may have significant potential for morbidity and mortality...
- Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndromeD N Mendhekar
J Neuropsychiatry Clin Neurosci 18:552-3. 2006
- Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndromeE Cem Atbasoglu
J Clin Psychiatry 65:1724-5. 2004
- Neuroleptic malignant syndrome and clozapine withdrawal at the same time?Branimir Margetic
Neuropsychiatric Hospital Dr Ivan Barbot, 44 317 Popovaca, Croatia
Prog Neuropsychopharmacol Biol Psychiatry 29:145-7. 2005..abrupt discontinuation of clozapine and haloperidol developed agitated and confused state resembling neuroleptic malignant syndrome (NMS) and clozapine withdrawal symptoms at the same time...
- Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndromeDebra L Stevens
Oklahoma DHS Developmental Disabilities Services Division, Oklahoma City, OK 73125, USA
Ann Pharmacother 42:1290-7. 2008To review the published reports of neuroleptic malignant syndrome (NMS) associated with the use of selective serotonin-reuptake inhibitors (SSRIs) and second-generation antipsychotics.
- Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatmentMurat Eren Ozen
Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
World J Biol Psychiatry 8:42-4. 2007b>Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders. We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone...
- Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patientR Bottlender
Department of Psychiatry, Ludwig Maximilians University, Munich
Pharmacopsychiatry 35:119-21. 2002b>Neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal complication of antipsychotic medication. The risk of developing NMS under atypical neuroleptics seems lower than under typical neuroleptics...
- Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published casesPaul E Croarkin
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
J Clin Psychiatry 69:1157-65. 2008To retrospectively examine published cases of neuroleptic malignant syndrome (NMS) in patients aged 18 and below who had been treated with atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and ..
- Neuroleptic malignant syndrome in cancer treatmentChiaki Kawanishi
Department of Psychiatry, Yokohama City University School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama 236 0004, Japan
Palliat Support Care 3:51-3. 2005b>Neuroleptic malignant syndrome (NMS) is a life-threatening reaction to neuroleptics. Several prospective studies have reported NMS occurrence rates ranging from 0.07% to 2.2% of patients receiving neuroleptics...
- Neuroleptic malignant syndrome in a child treated with an atypical antipsychoticIbrahim Abu-Kishk
Pediatric Intensive Care Unit, Assaf Harofeh Medical Center, Israel
J Toxicol Clin Toxicol 42:921-5. 2004b>Neuroleptic malignant syndrome (NMS) is an uncommon potentially fatal side effect of neuroleptic drugs, characterized by movement disorder, altered mental status and autonomic instability...
- Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysisKenneth R Kaufman
Department of Psychiatry, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
Ann Clin Psychiatry 18:201-4. 2006Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are medical emergencies associated with psychotropic administration...
- Managing an effective treatment for neuroleptic malignant syndromeUdo Reulbach
Department of Psychiatry and Psychotherapy, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
Crit Care 11:R4. 2007b>Neuroleptic malignant syndrome (NMS) is a rare, but sometimes fatal, adverse reaction to neuroleptics characterized principally by fever and rigor...
- Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapyNeeraj Berry
Department of Psychiatry, National Pharmacovigilance Centre, All India Institute of Medical Sciences, New Delhi, India
Pharmacotherapy 23:255-9. 2003..Classic neuroleptic malignant syndrome (NMS) was diagnosed...
- Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndromeA Suzuki
Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036 8562, Japan
Am J Psychiatry 158:1714-6. 2001The pathophysiology of neuroleptic malignant syndrome is mainly explained by a central hypodopaminergic state...
- A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazoleOrson P Rodriguez
St Anthony Family Medicine Residency, Oklahoma City, Oklahoma, USA
J Okla State Med Assoc 99:435-8. 2006b>Neuroleptic malignant syndrome (NMS) is a rare disorder seen most often in patients exposed to antipsychotic medications...
- Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challengeNicola S Gray
Department of Psychiatry, Allegheny General Hospital, Four Allegheny Center, 8th Floor, Pittsburgh, PA 15212 4772, USA
Hum Psychopharmacol 19:205-7. 2004A case of neuroleptic malignant syndrome (NMS) in a patient with Parkinson's disease (PD) is presented. The syndrome was precipitated by the atypical antipsychotic, ziprasidone...
- Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor geneI Kishida
Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan
Mol Psychiatry 9:293-8. 2004A genetic predisposition to the development of neuroleptic malignant syndrome (NMS) has been suggested by clinical studies...
- Ziprasidone- and lithium-induced neuroleptic malignant syndromeMary C Borovicka
College of Pharmacy, University of Toledo, Toledo, OH, USA
Ann Pharmacother 40:139-42. 2006To report a case of ziprasidone- and lithium-induced neuroleptic malignant syndrome (NMS).
- Clinical management of neuroleptic malignant syndromeV L Susman
New York Presbyterian Hospital, Westchester Division, USA
Psychiatr Q 72:325-36. 2001b>Neuroleptic malignant syndrome (NMS) continues to be an unpredictable and rare, but potentially fatal complication of antipsychotic medications...
- Case-control study of neuroleptic malignant syndromeP Sachdev
School of Psychiatry, University of New South Wales, Australia
Am J Psychiatry 154:1156-8. 1997The authors performed a case-control study of neuroleptic malignant syndrome to identify potential risk factors.
- Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapyChiaki Kawanishi
Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan
Am J Pharmacogenomics 3:89-95. 2003The pathogenetic mechanism of neuroleptic malignant syndrome (NMS), a potentially lethal adverse effect of antipsychotics, is not well understood...
- Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case reportAkiko Kobayashi
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan
Prog Neuropsychopharmacol Biol Psychiatry 30:1170-2. 2006..The present report is the first to describe a DLB patient who developed neuroleptic malignant syndrome (NMS) induced by quetiapine, an atypical neuroleptic known to have relatively infrequent ..
- Neuroleptic malignant syndrome: a reviewA L Pelonero
Department of Psychiatry at Virginia Commonwealth University Medical College of Virginia, Richmond 23298 0710, USA
Psychiatr Serv 49:1163-72. 1998b>Neuroleptic malignant syndrome is an uncommon side effect of antipsychotic medications characterized by severe rigidity, tremor, fever, altered mental status, autonomic dysfunction, and elevated serum creatinine phosphokinase and white ..
- Possible neuroleptic malignant syndrome with aripiprazole and fluoxetineHarpreet S Duggal
Am J Psychiatry 162:397-8. 2005
- Case study. Risperidone-Induced neuroleptic malignant syndrome in an adolescentA S Robb
Department of Psychiatry and Behavioral Science, The Children s National Medical Center, Washington, DC 20010, USA
J Child Adolesc Psychopharmacol 10:327-30. 2000b>Neuroleptic malignant syndrome (NMS) is a potentially fatal complication of neuroleptic therapy, characterized by fever, rigidity, mental status changes, and autonomic instability...
- Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's diseaseY Sato
Department of Neurology, Futase Social Insurance Hospital, Iizuka 820 0054, Japan
J Neurol Neurosurg Psychiatry 74:574-6. 2003b>Neuroleptic malignant syndrome (NMS) is a dangerous complication in patients with Parkinson's disease (PD).
- [Life threatening neuroleptic malignant syndrome due to olanzapine]Andrea Kopf
Psychiatr Prax 30:279-82. 2003The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature. A 49 year-old female patient developed NMS 12 days after olanzapine re-exposure...
- Neuroleptic malignant syndrome following administration of risperidone and lithiumJames A Bourgeois
J Clin Psychopharmacol 23:315-7. 2003
- Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderlyRyan C W Hall
Johns Hopkins Sinai Hospital, Department of Medicine, Baltimore, MD, USA
South Med J 98:114-7. 2005..After an extensive workup to rule out infection, the patient was diagnosed as having neuroleptic malignant syndrome (NMS)...
- [Olanzapine-associated neuroleptic malignant syndrome. A case report and favorable response to risperidone]E Lopez-Torres
Actas Esp Psiquiatr 35:145-6. 2007
- Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophreniaAhmed Aboraya
Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, USA
W V Med J 98:63-5. 2002..During this two-week period, this patient began to develop signs and symptoms of neuroleptic malignant syndrome (NMS)...
- Catatonia and neuroleptic malignant syndrome: two sides of a coin?E Vancaester
Dept of Neurology, University Hospital Gent, Gent, Belgium
Acta Neurol Belg 107:47-50. 2007..Since catatonia shares a number of symptoms with the neuroleptic malignant syndrome (NMS) and similar treatments can be used in both conditions, it has also been suggested that NMS and ..
- Neuroleptic malignant syndrome and catatonia in a patient with dementiaDhiren Singh
Aust N Z J Psychiatry 42:547-8. 2008
- [Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment]M Pezza
Cattedra di Anestesia e Rianimazione, , Napoli, Italy
Minerva Anestesiol 69:591-6. 2003..The causes of rhabdomyolysis are usually traumatic and non-traumatic, such as neuroleptic malignant syndrome and rhabdomyolysis associated to septicemia...
- [The life threatening adverse effects of psychotropic drugs: a case report]Ahmet Tiryaki
Kradeniz Teknik U Tip Fak, Psikiyatri AD Trabzon
Turk Psikiyatri Derg 17:147-51. 2006b>Neuroleptic malignant syndrome (NMS) is a rare idiosyncratic reaction to antipsychotic drugs that is potentially fatal...
- Movement disorders and the treatment of schizophreniaJohn Ellard
Balmoral Beach, NSW, Australia
Australas Psychiatry 12:409. 2004
- Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatoniaMax Fink
Prog Neuropsychopharmacol Biol Psychiatry 30:1182-3; author reply 1184-5. 2006
- [Drug-induced neuroleptic malignant syndrome]Hiroaki Jitsuiki
Nippon Naika Gakkai Zasshi 96:1627-33. 2007
- [Considerations in the combination of clozapine and benzodiazepines]R Rupprecht
Klinik für Psychiatrie und Psychotherapie der Ludwig Maximilians Universität München, Munchen, Deutschland
Nervenarzt 75:857-60. 2004..Moreover, the formulation of such guidelines would help with forensic issues in case of serious adverse events occurring during this combination therapy...
- [Lethal catatonia and its differential diagnosis with the neuroleptic malignant syndrome]L Andreu Gimenez
Rev Neurol 34:399-400. 2002
- Drug-induced catatoniaHarpreet S Duggal
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O Hara St, Pennsylvania 15213, USA
Drugs Today (Barc) 41:599-607. 2005..This article attempts to review the available literature in this realm and integrate the information in an attempt to explore the epidemiology, etiology, mechanism and treatment of drug-induced catatonia...
- Toxic interaction between risperidone and clozapine: a case reportVassilis P Kontaxakis
Department of Psychiatry, University of Athens, Eginition Hospital, Greece
Prog Neuropsychopharmacol Biol Psychiatry 26:407-9. 2002..of neurotoxicity, there are reports regarding various neurotoxic or idiosyncratic reactions including neuroleptic malignant syndrome (NMS)...
- Catatonia in psychiatric classificationFilip Van Den Eede
Am J Psychiatry 161:2327-8; author reply 2328. 2004
- Caution is still needed when prescribing atypical antipsychoticsStephen Carey
Br J Hosp Med (Lond) 69:299. 2008
- Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophreniaA Mane
J Child Adolesc Psychopharmacol 15:844-5. 2005
- Genetic predisposition to neuroleptic malignant syndrome in siblingsMarc Ziegenbein
Ann Pharmacother 40:574-5. 2006
- [Neuroleptic malignant syndrome after 30 years treatment with clozapine: a rarely seen differential diagnosis on intensive care units]D Franzen
Spital Zollikerberg, Medizinische Klinik, Zurich, Schweiz
Anasthesiol Intensivmed Notfallmed Schmerzther 41:125-7. 2006The neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal side effect of conventional and atypical antipsychotic drugs...
- [Neuroleptic malignant syndrome in users of risperidone]F Bonte-Mineur
Ned Tijdschr Geneeskd 149:158-9; author reply 159. 2005
- [Neuroleptic malignant syndrome in users of risperidone]T van Bemmel
Ned Tijdschr Geneeskd 149:608; author reply 608. 2005
- Comment: neuroleptic malignant syndrome associated with risperidone and fluvoxamineGeoffrey K Isbister
Ann Pharmacother 36:1293; author reply 1294. 2002
- [Neuroleptic malignant syndrome in users of risperidone]J A Van Waarde
Ned Tijdschr Geneeskd 149:156-7; author reply 157. 2005
- Neuroleptic malignant syndrome caused by combination of risperidone and lithium in a patient with multiple medical comorbiditiesSeyfullah Gorkem Kosehasanogullari
Prog Neuropsychopharmacol Biol Psychiatry 31:1147-8. 2007
- Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrheaU Patel
Division of Cardiology, Coney Island Hospital, New York, New York 11235, USA
J Natl Med Assoc 94:279-82. 2002b>Neuroleptic malignant syndrome is a rare (incidence, 0.02%-3.2%) but dangerous complication following the use of neuroleptic drugs. When not promptly recognized, this disease carries a high mortality (10%-20%) and morbidity rate...
- Atypical neuroleptic malignant syndrome associated with olanzapineRoy R Reeves
G V Sonny Montgomery Veterans Administration Medical Center, Jackson, Mississippi 39216, USA
Pharmacotherapy 22:641-4. 2002b>Neuroleptic malignant syndrome (NMS) is a potentially life-threatening adverse effect of antipsychotic agents. It generally is characterized by fever, altered mental status, rigidity, and autonomic dysfunction...
- Olanzapine induced "typical" neuroleptic malignant syndromeJoseph S Goveas
J Clin Psychopharmacol 23:101-2. 2003
- Neuroleptic malignant syndrome presenting with acute renal failureHarpreet S Duggal
Prog Neuropsychopharmacol Biol Psychiatry 32:1074-5. 2008
- Neuroleptic malignant syndrome and low-dose olanzapineHester Suh
Am J Psychiatry 160:796. 2003
- Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapyDebra L Stevens
University of Oklahoma College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, USA
Pharmacotherapy 28:403-5. 2008b>Neuroleptic malignant syndrome (NMS) is an idiosyncratic and uncommon but serious adverse effect that has been reported with both typical and atypical antipsychotic agents...
- Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patientsJordi Casademont
Muscle Research Unit, Internal Medicine Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
J Clin Psychopharmacol 27:284-8. 2007..It remains to be established if this finding in a nontarget tissue for antipsychotics may account for the lower incidence of movement disorders observed in patients on atypical agents...
- Pharmacotherapy for Minor DepressionRobert Howland; Fiscal Year: 2004..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
- Ecstasy and the Dorsomedial HypothalamusDANIEL RUSYNIAK; Fiscal Year: 2007....
- Multidisciplinary Study of Social Behavior and Emotion in Frontotemporal DementiaMario Mendez; Fiscal Year: 2009..This application combines many specialists to study disturbed social behavior in frontotemporal dementia. The results of the project can clarify how social behavior is altered by mental disorders or brain diseases. ..
- Multidisciplinary Study of Social Behavior and Emotion in Frontotemporal DementiaMARIO FERNANDO MENDEZ; Fiscal Year: 2010..This application combines many specialists to study disturbed social behavior in frontotemporal dementia. The results of the project can clarify how social behavior is altered by mental disorders or brain diseases. ..
- CNS circuitry and receptors mediating the effects of MDMADaniel E Rusyniak; Fiscal Year: 2010..of sympathetic, somatic motor and neuroendocrine systems: serotonin syndrome;cocaine toxicity, neuroleptic malignant syndrome;dysautonomia from brain injury, and heat stroke...